Background: Cerebral vasospasm is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). This study is designed to determine whether the incidence of symptomatic vasospasm and the overall clinical outcome differ between patients treated with surgical clipping compared with endovascular obliteration of aneurysms. Methods: In this prospective study, 98 patients with aneurysmal SAH were treated. Seventy-two patients underwent surgery and clipping and 26 had coil embolization. The incidence of symptomatic vasospasm, permanent neurologic deficit due to vasospasm and clinical outcome were analyzed. Patients with better clinical and radiological grades (World Federation of Neurological Surgeons grades I–III and Fisher grades I–III) were analyzed separately. Results: Symptomatic vasospasm occurred in 22% of the patients; 25% in the surgical group and 15% in the endovascular group. Nine percent of the patients in the surgical group and 7% in the endovascular group suffered ischemic infarction with permanent neurological deficit. These differences did not reach statistical significance (p = 0.42). For patients with better clinical and radiological grades, no significant difference was found for the rate of symptomatic vasospasm; 23% in the surgical and 12% in the endovascular group (p = 0.49). The overall clinical outcome was comparable in both groups, with no difference in the likelihood of a Glasgow Outcome Scale score of 3 or less (15% in the surgical and 16% in the endovascular group; p = 0.87). The same results for outcome were obtained for the subgroup of patients with better clinical grades on admission. Conclusion: Symptomatic vasospasm and ischemic infarction rate seem comparable in both groups, even for patients with better clinical and radiological admission grades. There is no significant difference in the overall clinical outcome at the long-term follow-up between both groups.

Keywords:
Subarachnoid hemorrhage, Aneurysm, Vasospasm, Clipping, Endovascular treatment
1.
Zabramski JM, Hamilton MG: Cerebral vasospasm; in Carter LP, Spetzler RF (eds): Neurovascular Surgery. New York, McGraw-Hill, 1995, pp 583–601.
2.
Adams HP Jr, Kassel NF, Torner JC: Predicting cerebral ischemia after aneurysmal subarchnoid hemorrhage: Influence of clinical condition, CT results and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987;37:1586–1591.
3.
Dorsch NW: Cerebral arterial spasm – A clinical review. Br J Neurosurg 1995;9:403–412.
4.
Saito I, Ueda Y, Sano K: Significance of vasospasm in the treatment of ruptured intracranial aneurysms. J Neurosurg 1977;47:412–429.
5.
Fisher CM, Kistler JP, Davis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computed tomographic scanning. Neurosurgery 1980;6:1–9.
6.
Kistler JP, Crowell RM, Davis KR, Heros R, Ojemann RG, Zervas CT, Fisher CM: The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT: A prospective study. Neurology 1983;33:424–436.
7.
Brouwers PJ, Dippel DW, Vermeulen M, et al: Amount of blood on computed tomography as an independent predictor after aneurysm rupture. Stroke 1993;24:809–814.
8.
Ohman J, Servo A, Heiskanen O: Risk factors for cerebral infarction in good-grade patients after aneurysmal subarachnoid hemorrhage and surgery: A prospective study. J Neurosurg 1991;74:14–20.
9.
Handa Y, Weir BK, Nosko M, Mosewich R, Tsuji T, Grace M: The effect of timing of clot removal on chronic vasospasm in a primate model. J Neurosurg 1987;67:558–564.
10.
Nosko M, Weir BK, Lunt A, Grace M, Allen P, Mielke B: Effect of clot removal at 24 hours on chronic vasospasm after SAH in the primate model. J Neurosurg 1987;66:416–422.
11.
Alexander E 3rd, Black PM, Liszczak TM, Zervas NT: Delayed CSF lavage for arteriographic and morphological vasospasm after experimental SAH. J Neurosurg 1985;63:949–958.
12.
Zabramski JM, Spetzler RF, Bonstelle C: Chronic cerebral vasospasm: Effect of volume and timing of hemorrhage in a canine model. Neurosurgery 1986;18:1–6.
13.
Inagawa T, Kamiya K, Matsuda Y: Effect of continuous cisternal drainage on cerebral vasospasm. Acta Neurochir (Wien) 1991;112:28–36.
14.
Inagawa T, Yamamoto M, Kamiya K: Effect of clot removal on cerebral vasospasm. J Neurosurg 1990;72:224–230.
15.
Kawakami Y, Shimamura Y: Cisternal drainage after early operation of ruptured intracranial aneurysm. Neurosurgery 1987;20:8–14.
16.
Mizukami M, Kawase T, Usami T, Tazawa T: Prevention of vasospasm by early operation with removal of subarachnoid blood. Neurosurgery 1982;10:301–307.
17.
Guglielmi G, Vinuela F, Dion J, Duckwiler G: Electrothrombosis of saccular aneurysms via endovascular approach. 2. Preliminary clinical experience. J Neurosurg 1991;75:8–14.
18.
Graves VB, Strother CM, Duff TA, Perl J 2nd: Early treatment of ruptured aneurysms with Guglielmi detachable coils: Effect of subsequent bleeding. Neurosurgery 1995;37:640–648.
19.
Gruber A, Ugersbock K, Reinprecht A, Czech T, Gross C, Bednar M, Richling B: Evaluation of cerebral vasospasm after early surgical and endovascular treatment of ruptured intracranial aneurysms. Neurosurgery 1998;42:258–268.
20.
Yalamanchili K, Rosenwasser RH, Thomas JE, Liebman K, McMorrow C, Gannon P: Frequency of cerebral vasospasm in patients treated with endovascular occlusion of intracranial aneurysms. AJNR Am J Neuroradiol 1998;19:553–558.
21.
Charpentier C, Audibert G, Guillemin F, et al: Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 1999;30:1402–1408.
22.
Kassel NF, Torner JC, Haley EC, Jane JA, Adams HP, Kongable GL: The international cooperative study on the timing of aneurysm surgery. 1. Overall management results. J Neurosurg 1990;73:18–36.
23.
Kassel NF, Torner JC, Jane JA, Haley EC, Adams HP: The international cooperative study on the timing of aneurysm surgery. 2. Surgical results. J Neurosurg 1990;73:37–47.
24.
Jennet B, Bond M: Assessment of outcome after severe brain damage: A practical scale. Lancet 1975;i:480–484.
25.
Drake CG: Report of the World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 1988;68:985–986.
26.
Fisher CM: Clinical syndromes in cerebral thrombosis, hypertensive hemorrhage and ruptured saccular aneurysms. Clin Neurosurg 1975;22:117–147.
27.
Macdonald RL, Wallace MC, Coyne TJ: The effect of surgery on the severity of vasospasm. J Neurosurg 1994;80:433–439.
28.
Mendelow AD: Pathophysiology of delayed ischaemic dysfunction after subarachnoid haemorrhage: Experimental and clinical data. Acta Neurochir Suppl (Wien) 1988;45:7–10.
29.
Nath FP, Jenkins A, Mendelow AD, Graham DI, Teasdale GM: Early hemodynamic changes in experimental intracerebral hemorrhage. J Neurosurg 1986;66:416–422.
30.
Sinar EJ, Mendelow AD, Graham DI, Teasdale GM: Experimental intracerebral hemorrhage. Effect of temporary mass lesion. J Neurosurg 1987;66:568–576.
31.
Findlay JM, MacDonald RL, Weir BKA, Grace MG: Surgical manipulation of primate cerebral arteries in established vasospasm. J Neurosurg 1991;75:425–432.
32.
Simeone FA, Ryan KG, Cotter JR: Prolonged experimental cerebral vasospasm. J Neurosurg 1968;29:357–366.
33.
Arutuinov AI, Baron MA, Majorova NA: The role of mechanical factors in the pathogenesis of short-term and prolonged spasm of the cerebral arteries. J Neurosurg 1974;40:459–472.
34.
Mayberg MR, Winn HR: Neurosurgery Clinics of North America: Cerebral Vasospasm. Philadelphia, Saunders, 1990, vol 1, pp 265–463.
35.
Koivisto T, Vanninen R, Hurskainen H, Saari T, Hernesniemi J, Vapalahti M: Outcomes of early surgery versus endovascular treatment of ruptured cerebral aneurysms. Stroke 2000;31:2369–2377.
36.
Koivisto T, Vanninen E, Vanninen R, Kuikka J, Halonen P, Hernesniemi J, Vapalahti M: Cerebral perfusion before and after endovascular or surgical treatment of acutely ruptured cerebral aneurysms: A 1-year prospective follow-up study. Neurosurgery 2002;51:312–326.
37.
International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group: ISAT of neurosurgical clipping versus endovascular coiling in 2,143 patients with ruptured intracranial aneurysms: A randomized trial. Lancet 2002;360:1267–1274.
38.
Qureshi AI, Sung GY, Razumovsky AY, Lane K, Straw RN, Ulatowski JA: Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med 2000;28:1228–1229.
39.
Rabb CH, Tang G, Chin LS: A statistical analysis of factors related to symptomatic cerebral vasospasm. Acta Neurochir (Wien) 1994;127:27–31.
40.
Yoshika S, Nagata S, Ohara S, Yuhi F, Sakata S, Matsuno H: A retrospective analysis of the outcomes of patients with aneurysmal subarachnoid hemorrhage: A focus on the prognostic factors. No Shinkei Geka 1996;24:733–738.
41.
Qureshi AI, Suarez JI, Bhardwaj A, Yahia AM, Tamargo RJ, Ulatowski JA: Early predictors of outcome in patients receiving hypervolemic and hypertensive therapy for symptomatic vasospasm after subarachnoid hemorrhage. Crit Care Med 2000;28:824–829.
42.
Nichols DA, Brown RD, Meyer FB: Clips or coils in subarachnoid hemorrhage? Lancet 2002;360:1262.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.